

REMARKS/ARGUMENTS

By the present amendment, all of the claims pending in the parent application have been replaced by new claims 36-73.

The present invention relates to an antiallergic pharmaceutical composition comprising (i) an antihistamine compound, (ii) an inhibitor of histamine synthesis and, optionally, (iii) an allergen or an isolated nucleic acid molecule comprising at least one polynucleotide sequence encoding said allergen, and said antihistamine compound, inhibitor, and optional allergen or isolated nucleic acid molecule being combined in the composition with a pharmaceutically acceptable carrier.

The allergen may be chosen from one of the major antigens or may be a mixture of major antigens of acarids able to induce an immune reaction. The antihistamine compound is preferably chosen from the group comprising: brompheniramine, cetirizine, fexofenadine, cyproheptadine, dexchlorpheniramine, hydroxyzine, ketotifene, loratidine, mequitazine, oxotomide, mizolastine, ebastine, astemizole, carbinoxamide, alimemazine, buclizine, cyclizine hydrochlorate, and doxylamine.

With respect to the rejections of record, it is believed that the present invention moots these rejections. The claimed invention is believed to comply with the enablement and written description requirements under 35 U.S.C. 112, first paragraph, for the reasons set forth in the previous amendment, which we have incorporated by reference.

The claims are also believed to be allowable over the references which were cited and applied in the parent application for the reasons set forth in the previous amendment, which we have also incorporated by reference.

The instant application is now believed to be in condition for allowance. Such allowance is respectfully solicited.


Should the Examiner believe an additional amendment is needed to place the case in condition for allowance, he is hereby invited to contact Applicants' attorney at the telephone number listed below.

No fee is believed to be due as a result of this amendment. Should the Commissioner determine that a fee is due, he is hereby authorized to charge said fee to Deposit Account No. 02-0184.

Respectfully submitted,

Emile Loria et al.

By


Barry L. Kelmachter
BACHMAN & LaPOINTE, P.C.
Reg. No. 29,999
Attorney for Applicants

Telephone: (203) 777-6628 ext. 112

Telefax: (203) 865-0297

Email: docket@bachlap.com

Date: August 30, 2004

I, Nicole Motzer, hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313" on August 30, 2004.

